Urology
Volume 72, Issue 6 , Pages 1298-1302 , December 2008

A Multi-Institutional Matched-Control Analysis of Adjuvant and Salvage Postoperative Radiation Therapy for pT3-4N0 Prostate Cancer

  • Edouard J. Trabulsi

      Affiliations

    • Department of Urology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania
    • ,
  • Richard K. Valicenti

      Affiliations

    • Department of Radiation Oncology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania
    • Corresponding Author InformationReprint requests: Richard K. Valicenti, MD, Department of Radiation Oncology, Thomas Jefferson University, 111 S. 11th St, Philadelphia, PA 19107
    • ,
  • Alexandra L. Hanlon

      Affiliations

    • Department of Biostatistics, Temple University, Philadelphia, Pennsylvania
    • ,
  • Thomas M. Pisansky

      Affiliations

    • Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota
    • ,
  • Howard M. Sandler

      Affiliations

    • Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan
    • ,
  • Deborah A. Kuban

      Affiliations

    • Department of Radiation Oncology, MD, Anderson Cancer Center, Houston, Texas
    • ,
  • Charles N. Catton

      Affiliations

    • Department of Radiation Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada
    • ,
  • Jeff M. Michalski

      Affiliations

    • Department of Radiation Oncology, Washington University, St. Louis, Missouri
    • ,
  • Michael J. Zelefsky

      Affiliations

    • Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York
    • ,
  • Patrick A. Kupelian

      Affiliations

    • Department of Radiation Oncology, Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, Ohio
    • ,
  • Daniel W. Lin

      Affiliations

    • Department of Urology, University of Washington School of Medicine, Seattle, Washington
    • ,
  • Mitchell S. Anscher

      Affiliations

    • Department of Radiation Oncology, Duke University School of Medicine, Durham, North Carolina
    • ,
  • Kevin M. Slawin

      Affiliations

    • Department of Urology, Baylor College of Medicine, Houston, Texas
    • ,
  • Claus G. Roehrborn

      Affiliations

    • Department of Urology, University of Texas-Southwestern Medical Center, Dallas, Texas
    • ,
  • Jeffrey D. Forman

      Affiliations

    • Department of Radiation Oncology, Wayne State University School of Medicine, Detroit, Michigan
    • ,
  • Stanley L. Liauw

      Affiliations

    • Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, Florida
    • ,
  • Larry L. Kestin

      Affiliations

    • Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, Michigan
    • ,
  • Theodore L. DeWeese

      Affiliations

    • Department of Radiation Oncology, Johns Hopkins University, Baltimore, Maryland
    • ,
  • Peter T. Scardino

      Affiliations

    • Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York
    • ,
  • Andrew J. Stephenson

      Affiliations

    • Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, Ohio
    • ,
  • Alan Pollack

      Affiliations

    • Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania

Received 16 January 2008 ,Accepted 13 May 2008.

References 

  1. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet. 2005;366:572–578
  2. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA. 2006;296:2329–2335
  3. Thompson IM, Tangen CM. Advanced prostate cancer and postoperative radiotherapy: reply. JAMA. 2007;297:951
  4. Swanson GP, Hussey MA, Tangen CM, et al. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol. 2007;25:2225–2229
  5. Grossfeld GD, Olumi AF, Connolly JA, et al. Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity. J Urol. 1998;159:1437–1443
  6. Valicenti RK, Gomella LG, Ismail M, et al. Pathologic seminal vesicle invasion after radical prostatectomy for patients with prostate carcinoma: effect of early adjuvant radiation therapy on biochemical control. Cancer. 1998;82:1909–19141998
  7. Valicenti RK, Gomella LG, Ismail M, et al. The efficacy of early adjuvant radiation therapy for pT3N0 prostate cancer: a matched-pair analysis. Int J Radiat Oncol Biol Phys. 1999;45:53–58
  8. Anscher MS, Prosnitz LR. Postoperative radiotherapy for patients with carcinoma of the prostate undergoing radical prostatectomy with positive surgical margins, seminal vesicle involvement and/or penetration through the capsule. J Urol. 1987;138:1407–1412
  9. Zietman AL, Coen JJ, Shipley WU, et al. Adjuvant irradiation after radical prostatectomy for adenocarcinoma of prostate: analysis of freedom from PSA failure. Urology. 1993;42:292–298discussion 298-299
  10. Gibbons RP, Cole BS, Richardson RG, et al. Adjuvant radiotherapy following radical prostatectomy: results and complications. J Urol. 1986;135:65–68
  11. Valicenti RK, Gomella LG, Ismail M, et al. Durable efficacy of early postoperative radiation therapy for high-risk pT3N0 prostate cancer: the importance of radiation dose. Urology. 1998;52:1034–1040
  12. Anscher MS, Clough R, Robertson CN, et al. Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate. Prostate Cancer Prostatic Dis. 2006;9:254–260
  13. Morris MM, Dallow KC, Zietman AL, et al. Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys. 1997;38:731–736
  14. McCarthy JF, Catalona WJ, Hudson MA. Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: early versus delayed treatment. J Urol. 1994;151:1575–1578
  15. Taylor N, Kelly JF, Kuban DA, et al. Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys. 2003;56:755–763
  16. Stephenson AJ, Shariat SF, Zelefsky MJ, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA. 2004;291:1325–1332
  17. Katz MS, Zelefsky MJ, Venkatraman ES, et al. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol. 2003;21:483–489
  18. Stephenson AJ, Scardino PT, Kattan MW, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007;25:2035–2041
  19. Jung C, Cookson MS, Chang SS, et al. Toxicity following high-dose salvage radiotherapy after radical prostatectomy. BJU Int. 2006;99:529–533
  20. Feng M, Hanlon AL, Pisansky TM, et al. Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy. Int J Radiat Oncol Biol Phys. 2007;68:1417–1423
  21. Valicenti RK, Gomella LG, Ismail M, et al. Effect of higher radiation dose on biochemical control after radical prostatectomy for PT3N0 prostate cancer. Int J Radiat Oncol Biol Phys. 1998;42:501–506
  22. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 1999;17:1499–1507
  23. Valicenti RK, Gomella LG, El-Gabry EA, et al. The multidisciplinary clinic approach to prostate cancer counseling and treatment. Semin Urol Oncol. 2000;18:188–191

PII: S0090-4295(08)00770-X

doi: 10.1016/j.urology.2008.05.057

Urology
Volume 72, Issue 6 , Pages 1298-1302 , December 2008

Article Tools

* Image Usage & Resolution